» Articles » PMID: 15840697

CD4+ CD25+ Regulatory T Cells Control the Induction of Antigen-specific CD4+ Helper T Cell Responses in Cancer Patients

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2005 Apr 21
PMID 15840697
Citations 69
Authors
Affiliations
Soon will be listed here.
Abstract

A proportion of cancer patients naturally develop CD4+ T-helper type 1 (Th1) cell responses to NY-ESO-1 that correlate with anti-NY-ESO-1 serum antibodies. To address the role of T-cell regulation in the control of spontaneous tumor immunity, we analyzed NY-ESO-1-specific Th1 cell induction before or after depletion of CD4+CD25+ T cells in vitro. While Th1 cells were generated in the presence of CD25+ T cells in cancer patients seropositive for NY-ESO-1, seronegative cancer patients and healthy donors required CD25+ T-cell depletion for in vitro induction of NY-ESO-1-specific Th1 cells. In vitro, newly generated NY-ESO-1-specific Th1 cells were derived from naive precursors, whereas preexisting memory populations were detectable exclusively in patients with NY-ESO-1 antibody. Memory populations were less sensitive than naive populations to CD4+CD25+ regulatory T cells. We propose that CD4+CD25+ regulatory T cells are involved in the generation and regulation of NY-ESO-1-specific antitumor immunity.

Citing Articles

In situ analysis of CCR8 regulatory T cells in lung cancer: suppression of GzmB CD8 T cells and prognostic marker implications.

Hayashi Y, Ueyama A, Funaki S, Jinushi K, Higuchi N, Morihara H BMC Cancer. 2024; 24(1):627.

PMID: 38783281 PMC: 11112935. DOI: 10.1186/s12885-024-12363-x.


Implications of regulatory T cells in anti-cancer immunity: from pathogenesis to therapeutics.

Dwivedi M, Tiwari S, Kemp E, Begum R Heliyon. 2022; 8(8):e10450.

PMID: 36082331 PMC: 9445387. DOI: 10.1016/j.heliyon.2022.e10450.


Cancer vaccines: past, present and future; a review article.

Grimmett E, Al-Share B, Alkassab M, Zhou R, Desai A, Rahim M Discov Oncol. 2022; 13(1):31.

PMID: 35576080 PMC: 9108694. DOI: 10.1007/s12672-022-00491-4.


Depletion of central memory CD8 T cells might impede the antitumor therapeutic effect of Mogamulizumab.

Maeda Y, Wada H, Sugiyama D, Saito T, Irie T, Itahashi K Nat Commun. 2021; 12(1):7280.

PMID: 34907192 PMC: 8671535. DOI: 10.1038/s41467-021-27574-0.


Construction of an Immune Cell Infiltration Score to Evaluate the Prognosis and Therapeutic Efficacy of Ovarian Cancer Patients.

Liu J, Wang Y, Yuan S, Wei J, Bai J Front Immunol. 2021; 12:751594.

PMID: 34745124 PMC: 8564196. DOI: 10.3389/fimmu.2021.751594.